IBA account plan
Particle accelerator technology leader
At a glance
IBA is a Belgian particle-accelerator group in proton therapy, dosimetry, radiopharma and industrial sterilization, with EUR 620.2 million sales in 2025.
IBA (Ion Beam Applications, Louvain-la-Neuve, Belgium) designs and builds particle accelerators for cancer treatment and diagnosis and for industrial uses such as medical device sterilization. It has four activities, Proton Therapy, Dosimetry, RadioPharma Solutions and Industrial Solutions, has sold 700+ accelerators and 80+ proton therapy centers, and has been a Certified B Corporation since 2021. In FY2025 net sales reached a record EUR 620.2 million (+24%), adjusted EBIT EUR 27.4 million and net result EUR 12.7 million, with 2,290 employees. The USA is its largest market, and the employee vehicle Sustainable Anchorage holds 20% of the capital and 30% of the voting rights.
Business units
Proton Therapy (IBA Clinical)
about 54% of 2025 group sales (EUR 334.3 million)Proteus®ONE and Proteus®PLUS proton therapy systems, plus operation, maintenance and upgrades on 47 active sites; IBA says it holds 42% of clinical rooms. Sales rose 57% in 2025 and adjusted EBIT returned to EUR 10.2 million; in H1 2026 sales grew 8% to EUR 167.7 million with 5 Proteus®ONE systems sold.
Dosimetry (IBA Clinical)
about 11% of 2025 group sales (EUR 65.7 million)Independent quality-assurance systems, phantoms, detectors and software for radiotherapy, proton therapy and medical imaging (myQA, QUASAR, PhantomX, Radcal). Sales fell 11% to EUR 30.8 million in H1 2026 with an adjusted EBIT loss, and a cost-reduction plan announced in March 2026 targets a return to profit in the second semester.
Industrial Solutions (IBA Technologies)
Rhodotron® electron-beam and X-ray systems, mainly for medical device sterilization as an alternative to ethylene oxide and cobalt-60, plus polymers, food and PFAS treatment. Orders slowed in 2025 and H1 2026 because of market overcapacity; Rhodotron® LITE launched in May 2026 for lower-capacity centres.
RadioPharma Solutions (IBA Technologies)
Cyclotrons, radiochemistry synthesizers (from the ORA acquisition) and IntegraLab® turnkey radiopharmacies for hospitals and radiopharmaceutical producers. It posted its highest order intake to date in 2025 and signed four cyclotrons for Shreeji (India) in Q1 2026. IBA Technologies, which also holds Engineering & Supply Chain, had sales of EUR 127.0 million in H1 2026 (+10%).
IBA Corporate (ventures)
Minority ventures led by Catherine Vandenborre: PanTera (Ac-225 joint venture with SCK CEN, H1 2026 revenue EUR 13.7 million), mi2-factory (semiconductors), Normandy HadronTherapy (carbon therapy) and the Discovery Lab incubator.
Strategic priorities
- Margin targets to 2028
- Revenue CAGR of 5-7% over 2024-2028, OpEx up to 30% of sales and adjusted EBIT around 10% of revenue by 2028; 2026 adjusted EBIT of at least EUR 32 million.
- Recurring revenue
- Move from a cyclical project-driven model to a multi-business accelerator platform with more service revenue; the EUR 1.6 billion backlog is around half services.
- Proton therapy adoption
- Grow adoption with clinical evidence and new techniques such as DynamicARC® and ConformalFLASH®, which received FDA IDE approval in June 2026, and expand in the US, Asia and the Gulf.
- Nuclear medicine value chain
- Combine cyclotron leadership, the ORA radiochemistry platform and alpha-therapy partnerships: PanTera for Ac-225 and Framatome and ACCELERATE.EU for At-211.
- Sterilization conversion
- Capture the regulatory shift from ethylene oxide and gamma to E-beam and X-ray, with the E-beam/X-ray share expected to rise to over 20% by 2035.
Latest results
In H1 2026 net sales rose 6% to EUR 323.7 million, with IBA Clinical at EUR 196.8 million (+4%) and IBA Technologies at EUR 127.0 million (+10%). Gross margin improved to 33.7% from 29.5%, adjusted EBIT reached EUR 17.6 million against EUR 10.6 million, and the net result was EUR 9.3 million after a loss of EUR 2.6 million a year earlier. Equipment order intake rose 64% to EUR 176 million, driven by proton therapy, while Industrial Solutions orders stayed weak. Net debt rose to EUR 81 million because of working capital and invoicing delays after the SAP S/4HANA go-live. IBA reiterated 2026 adjusted EBIT of at least EUR 32 million.
Investments and deals
- ORA Group acquisition
- Acquired 80% of ORA and 100% of OOC on 18 December 2025, adding automated PET synthesizers; it was financed by a EUR 50 million acquisition term loan.
- PhantomX acquisition
- Acquired Berlin-based PhantomX GmbH on 31 October 2025 for AI quality assurance in Dosimetry.
- PanTera Ac-225 capacity
- PanTera broke ground on a commercial-scale Actinium Production Center (operations expected 2028), and expansion with TerraPower Isotopes and IRE will triple capacity.
- SAP S/4HANA ERP
- The ERP went live in H1 2026, costing EUR 2.1 million in implementation and temporarily delaying invoicing.
- Astatine-211 cyclotron
- Launch of Cyclone® iKure for industrial-scale At-211 production, with Framatome applying for the first At-211 site in Nantes.
Challenges and risks
- Sterilization overcapacity
- Post-COVID investments created overcapacity in sterilization, cutting Industrial order intake; management expects a balanced market around 2028 to 2029.
- Working capital and net debt
- Back-ended Spanish proton therapy contracts and ERP invoicing delays lifted net debt to EUR 81 million at 30 June 2026, with marked improvement expected only in H2 2027.
- Dosimetry under pressure
- US and China tariffs, an adverse USD and pressure in conventional radiation therapy pushed Dosimetry to an adjusted EBIT loss in H1 2026.
- Lumpy orders and project delays
- A small number of large multi-year proton therapy orders drive sales, and delivery delays slow revenue and cash; competition comes from some of the world's largest corporations.
- Geopolitics and regulation
- US/China tariffs, the loss of control of the Russian subsidiary, country-by-country regulatory approvals and cybersecurity rules (NIS2, MDR, Cyber Resilience Act) are named risks.
What leadership says
“confirmed that IBA is on track with its improved profitability trajectory”
“Our view remains that this reflects a temporary imbalance between capacity and demand rather than a structural change in market fundamentals”
“for us, it's becoming a bit of a religion, 40%, 30%, 10%”
“The guidance that we give is like in 2025, one to beat and not necessarily to meet.”
Where a supplier can help
- Supply chain and manufacturing cost
- The gross margin target of 40% and Engineering & Supply Chain work on design-for-manufacturing and more local sourcing favour component suppliers and manufacturing partners that lower cost.
- ERP and finance operations
- Invoicing delays after the SAP S/4HANA go-live and working-capital pressure point to ERP support, billing and cash-management offers.
- Service productivity
- Service growth with system availability close to 97% while support workload rose 37%, and AI-enabled troubleshooting, suit field-service, remote monitoring and AI support tools.
- Radiopharma and theranostics ecosystem
- The nuclear medicine value chain priority (cyclotrons, ORA radiochemistry, Ac-225 and At-211) opens room for radiopharmacy equipment, consumables, regulatory and clinical partners.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like IBA?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- IBA Annual Report 2025
- IBA (Ion Beam Applications, Louvain-la-Neuve, Belgium) is a particle-accelerator group with four core activities: Proton Therapy, Dosimetry, RadioPharma Solutions and Industrial Solutions; 2,290 employees, 700+ accelerators sold, 80+ proton therapy centers sold, a Certified B Corporation since 2021.
- FY2025 was a record year: net sales EUR 620.2 million (+24% vs EUR 498.2 million), adjusted EBIT EUR 27.4 million (+58%, 4.4% of sales), net result EUR 12.7 million (+38%), EPS EUR 0.43; proposed gross dividend EUR 0.25 per share.
- Organised in three entities since 2025: IBA Clinical (Proton Therapy + Dosimetry, 64% of turnover, led by CEO Olivier Legrain), IBA Technologies (RadioPharma Solutions, Industrial Solutions, Engineering & Supply Chain, 36%, led by Deputy CEO Henri de Romrée) and IBA Corporate (ventures, led by CFO Catherine Vandenborre).
- Proton Therapy returned to profit: sales EUR 334.3 million (+57%), equipment sales +127%, adjusted EBIT EUR 10.2 million vs -EUR 12.1 million in 2024; 10 systems sold (9 Proteus®ONE, 1 Proteus®PLUS), 42% share of clinical rooms at end 2025.
- Equipment order intake EUR 452 million (+41%); backlog at an all-time high of EUR 1.6 billion (EUR 0.78 billion equipment, EUR 0.82 billion services); net debt EUR 58 million after the ORA acquisition (EUR 17 million).
- Management frames 2025 as an "inflection point": from a proton therapy equipment maker to a multi-business particle accelerator manufacturer, with more recurring service revenue and a push along the nuclear-medicine value chain (ORA radiochemistry acquisition, PanTera Ac-225 joint venture, At-211 projects with Framatome).
- Guidance: 2026 adjusted EBIT of at least EUR 32 million; 2024-2028 outlook of 5-7% revenue CAGR, OpEx up to 30% of sales and adjusted EBIT around 10% of revenue by 2028.
- Main risks named: lumpy multi-year proton therapy orders and project delivery delays, competition from much larger corporations, geopolitical and market-access constraints (US/China tariffs, loss of control of the Russian subsidiary), regulatory approvals, cybersecurity and key-skills retention.
- IBA Mid Year Report 2026 (interim condensed consolidated financial statements, June 30, 2026)
- H1 2026 net sales EUR 323.7 million (+6% vs EUR 304.9 million); IBA Clinical EUR 196.8 million (+4%), IBA Technologies EUR 127.0 million (+10%).
- Gross margin rose to 33.7% (29.5%); adjusted EBIT EUR 17.6 million (5.4% margin) vs EUR 10.6 million; net result EUR 9.3 million vs a net loss of EUR 2.6 million; EPS EUR 0.32.
- Proton Therapy keeps turning around: sales EUR 167.7 million (+8%), adjusted EBIT EUR 12.3 million vs -EUR 2.2 million; 5 Proteus®ONE systems sold (Rio de Janeiro, Portugal, 2 for Duke University Health System); 46 projects in backlog.
- Dosimetry under pressure: sales EUR 30.8 million (-11%), adjusted EBIT -EUR 0.5 million; cost-reduction plan announced in March 2026.
- Equipment order intake EUR 176 million (+64%), driven by IBA Clinical (EUR 148 million, +176%); IBA Technologies only EUR 28 million because of overcapacity in the sterilization market; backlog stable at EUR 1.6 billion.
- Net debt rose to EUR 81 million (working capital, invoicing delays from the SAP S/4HANA go-live); improvement expected in H2 2026, accelerating in 2027.
- Leadership change: Henri de Romrée (Deputy CEO) took strategic and operational responsibility for all activities, Olivier Legrain became Vice-Chairman, Catherine Vandenborre Chief Ventures & Corporate Officer; Joyce Hansen and Dr. Stephen Hahn joined the Board.
- FY2026 guidance of adjusted EBIT of at least EUR 32 million reiterated; 2024-2028 outlook (5-7% revenue CAGR, OpEx up to 30%, adjusted EBIT around 10% by 2028) confirmed.
- IBA Half Year 2026 results call transcript
- CEO Olivier Legrain: H1 2026 "confirmed that IBA is on track with its improved profitability trajectory"; revenue above EUR 320 million, adjusted EBIT EUR 17.6 million, net result EUR 9.3 million, 2026 guidance of at least EUR 32 million adjusted EBIT reiterated.
- Proton therapy market: 16 rooms sold globally in H1 vs two a year earlier; with partner CGN in China IBA secured a 50% market share; footprint to reach 93 sites after all installations.
- Deputy CEO Henri de Romrée calls sterilization overcapacity "a temporary imbalance between capacity and demand rather than a structural change", with balance expected around 2028 to 2029; no pricing pressure because IBA is the clear leader.
- Margin targets are "a bit of a religion": 40% gross margin, 30% OpEx, 10% EBIT; H1 Technologies margin is not the benchmark.
- Dosimetry: restructuring savings of EUR 1.6 million, mostly people-related; return to profitability expected in the second semester.
- Net debt EUR 81 million (1.14x adjusted EBITDA); relative stability in 2026, marked improvement in H2 2027 as Spanish proton projects ship (two in 2026, two in 2027, four in 2028; EUR 10 million paid per shipment).
- PanTera: H1 revenue EUR 13.7 million and EBITDA EUR 6.7 million; more than 40 Ac-225 clinical trials, three in phase III with first results from 2028; final Series A tranche to dilute IBA to 31%.
- IBA Full Year 2025 results call transcript
- CEO Olivier Legrain: 2025 "marks the inflection point from an historically cyclical project-driven model towards a more consistently profitable platform"; record revenue above EUR 620 million, adjusted EBIT EUR 27.4 million, proton therapy back to profit.
- Proton therapy: 12 rooms sold, 63% of the total sold globally in 2025; 45 operational sites and 43 systems in production and installation; adjusted EBIT EUR 10.2 million vs a EUR 12 million loss after EUR 8.7 million bad debt (two PT customers in China and the US).
- Pricing: on new contracts IBA is "back to where we want to be in terms of gross margin"; it wins on "genuine value of our proposal", not on price.
- Henri de Romrée: nuclear medicine strategy leverages accelerator leadership to expand along the value chain; ORA (about 15 employees) immediately accretive; focus on Actinium-225 and Astatine-211.
- CFO Catherine Vandenborre: revenue growth expected at the high end of the 5-7% range; 2026 guidance of at least EUR 32 million is "one to beat and not necessarily to meet"; net cash position expected at end 2027.
- Dosimetry stays in the portfolio: an exit rumour was "fake news"; cost measures should improve profitability in 2026.
- PanTera: EUR 13 million 2025 revenue, EBIT positive in Q4, valued at about EUR 290 million post-money in September 2024.
- Du cyclotron de laboratoire à l'entreprise au rayonnement mondial - Olivier Legrain at the École de Paris du management / La Fabrique de l'industrie (seminar of 25 March 2025)
- Seminar given by CEO Olivier Legrain at the École de Paris du management with La Fabrique de l'industrie on 25 March 2025: IBA's history, ownership model and value-creation plan (statements translated from French).
- Scale: 2,500 people, 1,200 in Belgium; more than 650 accelerators sold, more than 150,000 patients treated; 2024 revenue EUR 498 million with 12% spent on R&D; machines kept at up to 98% availability.
- Mix: proton therapy 50% of revenue, dosimetry 10%; competitors include Siemens, General Electric and Hitachi, so IBA must keep developing the next technology.
- Ownership: after a 1990s hostile bid by Nordion, employees bought the company through a leveraged employee buy-out; the employee vehicle, now Sustainable Anchorage, holds 20% of capital and 30% of voting rights; Legrain is drawn to steward-ownership.
- Proton therapy is used for under 1% of radiotherapy patients vs 20% justified; about 200 rooms exist vs 2,500 needed; cost of EUR 50-100 million is the main brake, so the aim is to treat more patients per machine (hypofractionation, FLASH).
- Value creation: more proton therapy, X-ray sterilization replacing ethylene oxide and cobalt, and investments in growth accelerators (theranostics with SCK CEN and Framatome, heavy-ion therapy in Normandy, a semiconductor start-up).
- China: IBA licensed its proton therapy technology in 2021 to a Chinese nuclear giant rather than face a local competitor; China is the first market, with about forty centres to open.
Questions about IBA
What does IBA do?
IBA designs and builds particle accelerators: proton therapy systems for cancer treatment, dosimetry quality-assurance tools, cyclotrons and radiochemistry for nuclear medicine, and electron-beam and X-ray systems for industrial sterilization.
What is IBA's revenue?
Net sales were a record EUR 620.2 million in FY2025, up 24%. H1 2026 net sales were EUR 323.7 million, up 6%.
How many employees does IBA have?
IBA had 2,290 employees of 73 nationalities in 2025.
What is IBA's strategy?
IBA aims to become a multi-business accelerator group with more recurring revenue, targeting 5-7% revenue CAGR over 2024-2028 and adjusted EBIT around 10% of revenue by 2028, while expanding along the nuclear-medicine value chain.
Who leads IBA?
Olivier Legrain, CEO since 2012, became Vice-Chairman in June 2026, when Deputy CEO Henri de Romrée took strategic and operational responsibility for all activities. Catherine Vandenborre is Chief Ventures & Corporate Officer, and the Board is chaired by Pierre Mottet.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)